Immuneering (Immuneering) Forward PE Ratio : 0.00 (As of May. 24, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Immuneering Forward PE Ratio?

Immuneering's Forward PE Ratio for today is 0.00.

Immuneering's PE Ratio without NRI for today is 0.00.

Immuneering's PE Ratio for today is 0.00.

Immuneering Forward PE Ratio Historical Data

The historical data trend for Immuneering's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuneering Forward PE Ratio Chart

Immuneering Annual Data

Trend

Forward PE Ratio

Immuneering Quarterly Data

Forward PE Ratio

Competitive Comparison of Immuneering's Forward PE Ratio

For the Biotechnology subindustry, Immuneering's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuneering's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuneering's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Immuneering's Forward PE Ratio falls into.

Immuneering Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Immuneering (NAS:IMRX) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Immuneering Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Immuneering's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuneering (Immuneering) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuneering Corp (NAS:IMRX) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Main Street, Second Floor, Cambridge, MA, USA, 02142

Website

https://www.immuneering.com

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.

Executives

Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Harold Eugene Brakewood	officer: Chief Business Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Leah R Neufeld	officer: Chief People Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Mallory Morales	officer: Vice President, Finance	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Brett Matthew Hall	officer: Chief Scientific Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Michael Bookman	officer: General Counsel and Secretary	C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Laurie Keating	director	300 THIRD STREET, CAMBRIDGE MA 02142
Biren Amin	officer: CFO, Treasurer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Benjamin J. Zeskind	director, 10 percent owner, officer: President and CEO	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Scott Barrett	officer: Chief Medical Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Peter Feinberg	director	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Ann E Berman	director	255 STATE STREET, BOSTON MA 02109